{"search_session":{},"preferences":{"l":"ru","queryLanguage":"ru"},"patentId":"159-490-351-618-920","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"159-490-351-618-920","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10797,"type":"PATENT","title":"University of Pittsburgh - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8047,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8262,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Univ* Pittsburgh\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents:5316
Search Applicants and Owners separately: \"Univ* Pittsburgh\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents:5316
introducing an enriched population of autologous, skeletal muscle-derived myoblasts into a site of injured, damaged, or dysfunctional urethra muscle tissue of a recipient, in an amount effective to ameliorate stress urinary incontinence."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the skeletal muscle-derived myoblasts are histocompatibly-matched with the recipient."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the skeletal muscle-derived myoblasts are introduced in a composition comprising a physiologically acceptable medium."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the skeletal muscle-derived myoblasts are introduced in an amount of about 105 to 106 cells per cm3 of tissue to be treated in a physiologically acceptable medium."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein a cloned population of the skeletal muscle-derived myoblasts is introduced into the recipient."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the skeletal muscle-derived myoblasts are contacted with a cytokine or growth factor selected from one or more of basic fibroblast growth factor (b-FGF), insulin-like growth factor (IGF), or nerve growth factor (NGF), prior to introducing the skeletal muscle-derived myoblasts into the recipient."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, further comprising isolating the skeletal muscle-derived myoblasts according to a culture method comprising:\n
(i) plating a suspension of cells from skeletal muscle tissue in a first container, to which fibroblast cells in the muscle tissue suspension adhere;\n
(ii) re-plating non-adherent cells from (i) in a second container after approximately 15% to 20% of the cells from the cell suspension have adhered to the first container;\n
(iii) repeating step (ii) at least one time to enrich for an end population of viable, non-fibroblast, desmin-expressing, skeletal muscle-derived myoblasts in the second container; and\n
(iv) isolating an end population of viable, non-fibroblast, desmin-expressing skeletal muscle-derived myoblasts in the culture."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of ameliorating stress urinary incontinence, comprising:\n
introducing an enriched population of autologous, skeletal muscle-derived myoblasts into a site of injured, damaged, or dysfunctional sphincter muscle tissue of a recipient, in an amount effective to ameliorate stress urinary incontinence."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the skeletal muscle-derived myoblasts are histocompatibly-matched with the recipient."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the skeletal muscle-derived myoblasts are introduced in a composition comprising a physiologically acceptable medium."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the skeletal muscle-derived myoblasts are introduced in an amount of about 105 to 106 cells per cm3 of tissue to be treated in a physiologically acceptable medium."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein a cloned population of the skeletal muscle-derived myoblasts is introduced into the recipient."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, wherein the skeletal muscle-derived myoblasts are contacted with a cytokine or growth factor selected from one or more of basic fibroblast growth factor (b-FGF), insulin-like growth factor (IGF), or nerve growth factor (NGF), prior to introducing the skeletal muscle-derived myoblasts into the recipient."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8, further comprising isolating the skeletal muscle-derived myoblasts according to a culture method comprising:\n
(i) plating a suspension of cells from skeletal muscle tissue in a first container, to which fibroblast cells in the muscle tissue suspension adhere;\n
(ii) re-plating non-adherent cells from (i) in a second container after approximately 15% to 20% of the cells from the cell suspension have adhered to the first container;\n
(iii) repeating step (ii) at least one time to enrich for an end population of viable, non-fibroblast, desmin-expressing, skeletal muscle-derived myoblasts in the second container; and\n
(iv) isolating an end population of viable, non-fibroblast, desmin-expressing skeletal muscle-derived myoblasts in the culture."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method of ameliorating stress urinary incontinence, comprising:\n
introducing an enriched population of autologous, skeletal muscle-derived myoblasts into a site of injured, damaged, or dysfunctional muscle tissue selected from urethra muscle tissue, sphincter muscle tissue, or a combination thereof, of a recipient, in an amount effective to ameliorate stress urinary incontinence."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein the skeletal muscle-derived myoblasts are histocompatibly-matched with the recipient."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein the skeletal muscle-derived myoblasts are introduced in a composition comprising a physiologically acceptable medium."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein the skeletal muscle-derived myoblasts are introduced in an amount of about 105 to 106 cells per cm3 of tissue to be treated in a physiologically acceptable medium."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein a cloned population of the skeletal muscle-derived myoblasts is introduced into the recipient."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein the skeletal muscle-derived myoblasts are contacted with a cytokine or growth factor selected from one or more of basic fibroblast growth factor (b-FGF), insulin-like growth factor (IGF), or nerve growth factor (NGF), prior to introducing the skeletal muscle-derived myoblasts into the recipient."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, further comprising isolating the skeletal muscle-derived myoblasts according to a culture method comprising:\n
(i) plating a suspension of cells from skeletal muscle tissue in a first container, to which fibroblast cells in the muscle tissue suspension adhere;\n
(ii) re-plating non-adherent cells from (i) in a second container after approximately 15% to 20% of the cells from the cell suspension have adhered to the first container;\n
(iii) repeating step (ii) at least one time to enrich for an end population of viable, non-fibroblast, desmin-expressing, skeletal muscle-derived myoblasts in the second container; and\n
(iv) isolating an end population of viable, non-fibroblast, desmin-expressing skeletal muscle-derived myoblasts in the culture."],"number":21,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}